Andersen Global Adds Dimension to European Footprint with Allyum in Belgium
Andersen Global bolsters its platform in Europe through a Collaboration Agreement with Allyum, a leading Mergers & Acquisitions (M&A) firm in Belgium, adding another dimension to the tax and legal platform in the region.
Founded in 2004 by Managing Director Raphaël Abou, Allyum specializes in comprehensive financial services for mid-cap companies with a specific focus on managing sell-side transactions from start to finish. The firm has expertise in mergers and acquisitions, private placements, IPO advisory, corporate venturing, shareholder restructuring, and financial analysis and planning.
“Over the past decade, we've assisted hundreds of companies on successful transactions and developed excellent relationships with the investment funds in our region,” Raphaël said. “Our collaboration with Andersen Global represents an exciting opportunity to apply our comprehensive approach to financial advisory through an unmatched global platform.”
"As we continue to expand our global M&A capabilities, Raphaël, his Partner Martin Delépine and their team bring invaluable expertise and a new dimension to our existing client relationships,” said Mark L. Vorsatz, Global Chairman and CEO of Andersen. "The experience Allyum brings will be immensely valuable for our clients navigating the M&A landscape in Belgium and across Europe.”
Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 18,000 professionals worldwide and a presence in over 500 locations through its member firms and collaborating firms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206717985/en/
Contacts
Megan Tsuei
Andersen Global
415-764-2700
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Join the 2025 Global Challenger Innovation Contest: Driving Inclusion Through Innovation28.3.2025 17:12:00 EET | Press release
The 10x1000 Tech for Inclusion community and next-generation corporate venture partner xcube.co launched the Global Challenger Innovation Contest 2025 at the JUMPSTARTER 2025 event in Hong Kong SAR, China, building on the success of the 2024 competition. Now in its second year, the contest continues to empower visionaries to create tech-driven solutions that promote inclusion and drive social impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328955793/en/ 10x1000 Tech for Inclusion and xcube.co jointly launched the Global Challenger Innovation Contest in Hong Kong SAR, China, at the JUMPSTARTER 2025 event. The Global Challenger Innovation Contest was inaugurated in 2024 as a flagship project of 10x1000 Tech for Inclusion, a global initiative supported by the International Finance Corporation (IFC) and Ant International, to empower emerging tech leaders to create innovative solutions for financial inclusion and social
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category28.3.2025 15:22:00 EET | Press release
Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327305519/en/ Altasciences receives a 2025 CDMO Leadership Award in the Small Molecule Dosage Form (North America) category. Altasciences’ CDMO site supports drug development with formulation, manufacturing, and analytical testing—from discovery to commercialization. Their FDA-inspected facility features Grade C cleanrooms, R&D and analytical labs, ICH stability chambers, and a cGMP warehouse. "This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” says Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are gratefu
SES and SpeQtral Sign MoU to Advance Global Quantum-Secure Communications28.3.2025 14:49:00 EET | Press release
SES and SpeQtral signed a Memorandum of Understanding (MoU) to develop an interoperable Optical Ground Station (OGS) to establish long-distance satellite-based Quantum Key Distribution (QKD) between Asia and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328851677/en/ SES's CEO Adel Al-Saleh and SpeQtral's CEO Chune Yang Lum sign a Memorandum of Understanding to develop an interoperable Optical Ground Station to establish long-distance satellite-based Quantum Key Distribution between Asia and Europe. Under the agreement, the development of an interoperable OGS will enable SES and SpeQtral to connect both companies’ current and future QKD satellite missions, resulting in easier access to, and diversity in the supply of long-distance QKD to end users in Asia, Europe and other future compatible ground stations worldwide. The integration of this proposed OGS with Singapore’s fibre-QKD network will help future customer
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 13:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Total revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inc
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 13:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom